UNITED STATES
                SECURITIES AND EXCHANGE COMMISSION
                     Washington, D.C.  20549

                           FORM 10-QSB


[X]    QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
       EXCHANGE ACT OF 1934

       For quarterly period ended September 30, 2005

[ ]    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
       SECURITIES EXCHANGE ACT OF 1934


                  Commission File No.  000-30991

             SKINOVATION PHARMACEUTICAL INCORPORATED
   (Name of small business issuer as specified in its charter)


                 NEVADA                       87-0458170
       (State of incorporation)  (I.R.S. Employer Identification No.)

                      2157 S. Lincoln Street
                    Salt Lake City, Utah 84106
                          (801) 323-2395
  (Address and telephone number of principal executive offices)

Check whether the issuer (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.
Yes [X]   No [ ]

Indicate by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Exchange Act).   Yes [X]   No [ ]

As of October 25, 2005 Skinovation Pharmaceutical Incorporated had a total of
708,000 shares of common stock issued and outstanding.

Transitional small business disclosure format:  Yes [ ]  No [X]

<PAGE>


                        TABLE OF CONTENTS

                  PART I: FINANCIAL INFORMATION

Item 1.  Financial Statements.........................................2

Item 2.  Plan of Operation............................................8

Item 3.  Controls and Procedures......................................8

                    PART II: OTHER INFORMATION

Item 6.  Exhibits.....................................................9

Signatures............................................................9




                 PART I:   FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

The financial information set forth below with respect to our statements of
operations for the three and nine month periods ended September 30, 2005 and
2004 is unaudited.  This financial information, in the opinion of management,
includes all adjustments consisting of normal recurring entries necessary for
the fair presentation of such data.  The results of operations for the nine
month period ended September 30, 2005 are not necessarily indicative of
results to be expected for any subsequent period.



                                2

<PAGE>








                 Skinovation Pharmaceutical Inc.

                       Financial Statements

                        September 30, 2005



                                3

<PAGE>






                 Skinovation Pharmaceutical, Inc.
                  (A Development Stage Company)
                          Balance Sheets
                              ASSETS



                                                   September 30, December 31,
                                                       2005         2004
                                                  ------------- -------------
                                                    (Unaudited)

CURRENT ASSETS
  Cash                                            $      1,143  $      3,037
                                                  ------------- -------------

  TOTAL ASSETS                                    $      1,143  $      3,037
                                                  ============= =============

               LIABILITIES AND STOCKHOLDER' EQUITY

CURRENT LIABILITIES

Accounts Payable - Related party                  $     33,776  $     33,776
Accounts Payable - Other                                 5,000         5,168
                                                  ------------- -------------

  Total Liabilities                                     38,776        38,944
                                                  ------------- -------------
STOCKHOLDERS' EQUITY

Common Stock, $.001 par value;
  50,000,000 shares authorized;
  708,000 shares issued and outstanding                    708           708

Additional Paid in Capital                              25,148        25,148

Deficit Accumulated During the Development Stage       (63,489)      (61,763)
                                                  ------------- -------------

  Total Stockholders' Equity                           (37,633)      (35,907)
                                                  ------------- -------------

  TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY      $      1,143  $      3,037
                                                  ============= =============



                                4

<PAGE>

                 Skinovation Pharmaceutical, Inc.
                  (A Development Stage Company)
                     Statement of Operations
                           (Unaudited)



<TABLE>
<CAPTION>
                                                                                        From
                                                                                        Inception on
                            For the three  For the three  For the nine   For the nine   January 15,
                            months ended   months ended   months ended   months ended   1988
                            Sept. 30,      Sept. 30,      Sept. 30,      Sept. 30,      to Sept. 30,
                            2005           2004           2005           2004           2005
                            -------------- -------------- -------------- -------------- --------------

                         <c>            <c>            <c>            <c>            <c>

REVENUES                    $           -  $           -  $           -  $           -  $      27,937
                            -------------- -------------- -------------- -------------- --------------
EXPENSES
  General & Administrative            222            496          1,726          1,802        128,501
                            -------------- -------------- -------------- -------------- --------------

    TOTAL EXPENSES                    222            496          1,726          1,802        128,501
                            -------------- -------------- -------------- -------------- --------------
NET LOSS BEFORE
 DISCONTINUED OPERATIONS             (222)          (496)        (1,726)        (1,802)      (100,564)

GAIN ON DISPOSAL
 OF OPERATIONS                          -              -              -              -         37,075
                            -------------- -------------- -------------- -------------- --------------

NET INCOME (LOSS)           $        (222) $        (496) $      (1,726) $      (1,802) $     (63,489)
                            ============== ============== ============== ============== ==============

NET LOSS PER SHARE          $           -  $           -  $           -  $           -  $       (0.16)
                            ============== ============== ============== ============== ==============
WEIGHTED AVERAGE SHARES
 OUTSTANDING                      708,000        708,000        708,000        708,000        392,958
                            ============== ============== ============== ============== ==============





                                        5
</TABLE>
<PAGE>
<TABLE>
<CAPTION>




                         Skinovation Pharmaceutical, Inc.
                           (A Development Stage Company)
                             Statement of Cash Flows
                                   (Unaudited)

                                                                               From
                                                                               Inception on
                                                                               January 15,
                                                  For the nine months ended    1988
                                                         September 30,         Through
                                                 ----------------------------- September 30,
                                                       2005          2004      2005
                                                 -------------- -------------- --------------

                                              <c>            <c>            <c>
Cash Flows from Operating Activities
  Net Loss                                       $      (1,726) $      (1,802) $     (63,489)
  Less Non-cash Items:
  Shares issued for services                                 -              -         10,433
  Shares issued for debt payment                             -              -          1,424
  Increase in accounts payable                            (168)         5,000         38,776
  Loss on disposal of PP&E                                   -              -          5,263
                                                 -------------- -------------- --------------

  Net Cash Provided (Used) by Operating Activities      (1,894)         3,198         (7,593)
                                                 -------------- -------------- --------------
Cash Flows from Investing Activities
  Cash paid for PP&E                                         -              -         (5,264)
                                                 -------------- -------------- --------------

  Net Cash Provided (Used) by Investing Activities           -              -         (5,264)
                                                 -------------- -------------- --------------
Cash Flows from Financing Activities
  Cash paid for offering costs                               -              -         (7,000)
  Common stock issued for cash                               -              -         21,000
                                                 -------------- -------------- --------------

  Net Cash Provided (Used) by Financing Activities           -              -         14,000
                                                 -------------- -------------- --------------

Increase (Decrease) in Cash                             (1,894)         3,198          1,143

Cash and Cash Equivalents at Beginning of Period         3,037              -              -
                                                 -------------- -------------- --------------

Cash and Cash Equivalents at End of Period       $       1,143  $       3,198  $       1,143
                                                 ============== ============== ==============

Supplemental Cash Flow Information:

  Stock issued for debt payment                  $           -  $           -  $       1,424
  Stock issued for services                      $           -  $           -  $      10,433

  Cash Paid For:
    Interest                                     $           -  $           -  $           -
    Income Taxes                                 $           -  $           -  $           -



                                        6


</TABLE>
<PAGE>


                 Skinovation Pharmaceutical Inc.
                Notes to the Financial Statements
                        September 30, 2005


GENERAL

Skinovation Pharmaceutical Inc. (the Company) has elected to omit
substantially all footnotes to the financial statements for the nine months
ended September 30, 2005 since there have been no material changes (other than
indicated in other footnotes) to the information previously reported by the
Company in their Annual Report filed on the Form 10-KSB for the twelve months
ended December 31, 2004.

UNAUDITED INFORMATION

The information furnished herein was taken from the books and records of the
Company without audit.  However, such information reflects all adjustments
which are, in the opinion of management, necessary to properly reflect the
results of the interim period presented.  The information presented is not
necessarily indicative of the results from operations expected for the full
fiscal year.





                                7

<PAGE>


In this report references to "Skinovation," "we," "us," and "our" refer to
Skinovation Pharmaceutical Incorporated.


        SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

The Securities and Exchange Commission ("SEC") encourages companies to
disclose forward-looking information so that investors can better understand
future prospects and make informed investment decisions.  This report contains
these types of statements.  Words such as "may," "will," "expect," "believe,"
"anticipate," "estimate," "project," or "continue" or comparable terminology
used in connection with any discussion of future operating results or
financial performance identify forward-looking statements.  You are cautioned
not to place undue reliance on the forward-looking statements, which speak
only as of the date of this report.  All forward-looking statements reflect
our present expectation of future events and are subject to a number of
important factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.

ITEM 2.  PLAN OF OPERATION

During the next twelve months our management intends to actively seek an
operating company to acquire or merge with which may provide operating
revenue.  Based on current economic and regulatory conditions, management
believes that it is possible, if not probable, for a company like ours,
without many assets or liabilities, to negotiate a merger or acquisition with
a viable private company.  The opportunity arises principally because of the
high legal and accounting fees and the length of time associated with the
process of "going public."  However, should a merger or acquisition prove
unsuccessful, it is possible that we may decide not to pursue further
acquisition activities and management may abandon its activities and our
shares would become worthless.

As of the date of this filing, we have not identified any assets or business
opportunities for acquisition.  Potential investors must recognize that
because of limited capital available for investigation of business
opportunities and management's limited experience in business analysis, we may
not discover or adequately evaluate adverse facts about any business
opportunity to be acquired.  All risks inherent in new and inexperienced
enterprises are inherent in our plan.

It is emphasized that our management may effect transactions having a
potentially adverse impact upon our shareholders pursuant to the authority and
discretion of our management to complete acquisitions without submitting any
proposal to the stockholders for their consideration.

As of September 30, 2005 we had $1,143 cash on hand and total current
liabilities of $38,776.  The majority of our operating expenses are related to
our reporting obligations under the Exchange Act.  These expenses include
legal, accounting and professional services required to prepare our reports
and the costs of filing the reports with the SEC.  We are unable to pay cash
for these services and have relied on related and third parties to pay for
these costs on our behalf.  These parties have not entered into written
agreements guaranteeing advances and, therefore, they are not obligated to
provide funds in the future.  However, management anticipates that these
parties will continue to pay for these costs on our behalf during the next
twelve months.  We may pay for these advances by converting the debt into
common stock.

ITEM 3.  CONTROLS AND PROCEDURES

Our President, who acts in the capacity of principal executive officer and
principal financial officer, has evaluated the effectiveness of our disclosure
controls and procedures as of the end of the period covered by this report.
Based on that evaluation, he concluded that our disclosure controls and
procedures were effective.

Also, he determined that there were no changes made in our internal controls
over financial reporting during the third quarter of 2005 that have materially
affected, or are reasonably likely to materially affect our internal control
over financial reporting.


                                8

<PAGE>


                   PART II:  OTHER INFORMATION

ITEM 6.  EXHIBITS

Part I Exhibits

31.1   Principal Executive Officer Certification
31.2   Principal Financial Officer Certification
32.1   Section 1350 Certification

Part II Exhibits

3.1    Articles of Incorporation as amended  (Incorporated by reference to
       exhibit 3.1 of the Form 10-KSB, filed March 29, 2002)
3.2    Bylaws of Skinovation (Incorporated by reference to exhibit 3.3 of the
       Form-SB, filed July 11, 2000)




                            SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.


                                   SKINOVATION PHARMACEUTICAL INCORPORATED


                                    /S/ John W. Peters
Date: November 8, 2005         By: ________________________________________
                                   John W. Peters
                                   President, Principal Executive Officer,
                                   Principal Financial Officer, and Director


                                9